BerGenBio, Oncoinvent merger nears completion, new entity to trade as Oncoinvent ASA

BerGenBio and Oncoinvent have announced key dates for their statutory triangular merger, expected to occur on 29 October 2025. Oncoinvent will cease trading on Euronext Growth Oslo the same day, with the combined entity commencing trading on the Oslo Stock Exchange on 30 October 2025 under the new name "Oncoinvent ASA" and ticker "ONCIN." BerGenBio’s current ticker will be adopted by the merged company, facilitated by Oncoinvent changing its ticker to "ONCOI" on 28 October 2025.

Former Oncoinvent shareholders will receive 1.202680493545220 shares in BerGenBio for each Oncoinvent share held as of the 31 October 2025 record date. A total of 117,554,012 consideration shares will be issued by BerGenBio, leading to a new share capital of NOK 156,641,128, divided into 156,641,128 shares. Share delivery is scheduled for 3 November 2025.

Further details regarding the merger are anticipated in a prospectus slated for publication on 28 October 2025.